Cardior hannover
WebJun 24, 2024 · HANOVER, Germany I June 24, 2024 I Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) … WebAug 26, 2024 · In 2024 he became additional director of the Center of Translational Regenerative Medicine at Hannover Medical School and since January 2024 serves as new director of the Fraunhofer Institute for Toxicology and Experimental Medicine in Hannover, Germany. He is recent founder and CSO of Cardior Pharmaceuticals GmbH, that so far …
Cardior hannover
Did you know?
WebMar 2, 2024 · HANOVER, Germany--(BUSINESS WIRE)-- Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the expansion of its Scientific Advisory Board (SAB) with four newly appointed cardiology and RNA drug development … WebAug 2, 2024 · Hannover, Germany: 00000 000: Cardior: Chief Medical Officer: 25-Aug-2024: Hannover, Germany: Fund Team Members (9) Name Investor Fund Fund Location Contact Info; Philip Scheltens: EQT Life Sciences: Life Sciences Partners 6: Amsterdam, Netherlands: John De Koning Ph.D: EQT Life Sciences: Life Sciences Partners 6:
WebOversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion Hanover, … WebApr 14, 2024 · Thomas joined Hannover Medical School in late 2009, to contribute to fibrosis research in interdisciplinary transplantation projects, and especially to bring his expertise in ncRNAs, on which he had already worked as the leader of a junior group on ‘Cardiac Wounding and Healing’ at the Interdisciplinary Center for Clinical Research of …
WebCardior General Information. Description. Operator of a biopharmaceutical platform intended to focus on the discovery, development, and clinical validation of noncoding RNA therapeutics. WebFounded Date 2016. Founders Claudia Ulbrich, Thomas Thum. Operating Status Active. Last Funding Type Series B. Company Type For Profit. Contact Email [email protected]. Phone Number +49 (0)511-33 85 99 30. …
WebJul 1, 2024 · July 01, 2024 05:00 AM Eastern Daylight Time. HANOVER, Germany-- ( BUSINESS WIRE )-- Cardior Pharmaceuticals GmbH, a clinical-stage biotech company …
WebAug 27, 2024 · Cardior Pharmaceuticals is an academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of … masters pipeline services bristolWebProffesional Building#2. 22201 Moros Rd St John Hospital And Medical Center, Detroit, MI, 48236. (313) 343-7774. masters pizza coupon codesWebAug 25, 2024 · Cardior Dr. Claudia Ulbrich / Barbara Gaertner-Rupprecht Cardior Pharmaceuticals GmbH Tel: +49 511 33 85 99 30 Media Inquiries Trophic … masters pimento cheeseWebApr 9, 2024 · Cardior Pharmaceuticals Founded by Thomas Thum in the year 2016 · Revenue stood at $86.8K · Developer of microRNA technology to predict and treat cardiovascular diseases. ... Hannover, Germany. Company Stage. Series B. Total Funding. $92.3M. Latest Funding Round. $76M, Series B, Aug 25, 2024. masters pizza coupon codeWebJun 24, 2024 · HANOVER, Germany I June 24, 2024 I Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that results from a recent peer-reviewed study underlining the Company´s pioneering approach in … masters pizza buffalo nyWebFounded Date 2016. Founders Claudia Ulbrich, Thomas Thum. Operating Status Active. Last Funding Type Series B. Company Type For Profit. Contact Email [email protected]. Phone Number +49 (0)511-33 85 99 30. Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the … masters pimento cheese spreadWebNov 3, 2024 · Hanover, Germany, December 1, 2024 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for … Our goal at Cardior is to identify and counteract the molecular mechanisms of … Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical … CDR132L, Cardior’s lead compound, is designed to halt and reverse detrimental … Hanover, Germany, July 20, 2024 – Cardior Pharmaceuticals, a clinical-stage … masters pizza livingston nj